TY - JOUR
T1 - Validity and responsiveness of the Daily-and Clinical visit-PROactive Physical Activity in COPD (D-PPAC and C-PPAC) instruments
AU - Garcia-Aymerich, Judith
AU - Puhan, Milo A.
AU - Corriol-Rohou, Solange
AU - De Jong, Corina
AU - Demeyer, Heleen
AU - Dobbels, Fabienne
AU - Erzen, Damijan
AU - Frei, Anja
AU - Gimeno-Santos, Elena
AU - Hopkinson, Nicholas S.
AU - Ivanoff, Nathalie
AU - Karlsson, Niklas
AU - Louvaris, Zafeiris
AU - Polkey, Michael I.
AU - Rabinovich, Roberto A.
AU - Scuri, Mario
AU - Tabberer, Maggie
AU - Vogiatzis, Ioannis
AU - Troosters, Thierry
N1 - Funding Information:
Competing interests JG-A reports other from AstraZeneca, other from Esteve, other from Chiesi, other from Menarini, outside the submitted work. SC-R reports personal fees from AstraZeneca, outside the submitted work. DE reports personal fees from Boehringer Ingelheim, outside the submitted work. NI reports personal fees from Almirall, outside the submitted work. NK reports personal fees from AstraZeneca, outside the submitted work. MIP reports personal fees from Philips, grants, personal fees and non-financial support from GSK, during the conduct of the study. MS reports personal fees from Chiesi, outside the submitted work. MT reports personal fees and other from GSK, outside the submitted work. TT reports grants from IMI-JU PROactive grant, during the conduct of the study; other from Boehringer Ingelheim, other from AZ Belgium, outside the submitted work.
Funding Information:
Funding Supported by the European Commission Innovative Medicines Initiative Joint Undertaking [IMI JU number 115011]. This project was also supported by the NIHR Respiratory Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College who part-funded MIP’s salary. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the ’Centro de Excelencia Severo Ochoa 2019-2023’ Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. HD is a postdoctoral research fellow of the FWO Flanders.
Publisher Copyright:
© Author(s) (or their employer(s)) 2021.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Background The Daily-PROactive and Clinical visit-PROactive Physical Activity (D-PPAC and C-PPAC) instruments in chronic obstructive pulmonary disease (COPD) combines questionnaire with activity monitor data to measure patients' experience of physical activity. Their amount, difficulty and total scores range from 0 (worst) to 100 (best) but require further psychometric evaluation. Objective To test reliability, validity and responsiveness, and to define minimal important difference (MID), of the D-PPAC and C-PPAC instruments, in a large population of patients with stable COPD from diverse severities, settings and countries. Methods We used data from seven randomised controlled trials to evaluate D-PPAC and C-PPAC internal consistency and construct validity by sex, age groups, COPD severity, country and language as well as responsiveness to interventions, ability to detect change and MID. Results We included 1324 patients (mean (SD) age 66 (8) years, forced expiratory volume in 1 s 55 (17)% predicted). Scores covered almost the full range from 0 to 100, showed strong internal consistency after stratification and correlated as a priori hypothesised with dyspnoea, health-related quality of life and exercise capacity. Difficulty scores improved after pharmacological treatment and pulmonary rehabilitation, while amount scores improved after behavioural physical activity interventions. All scores were responsive to changes in self-reported physical activity experience (both worsening and improvement) and to the occurrence of COPD exacerbations during follow-up. The MID was estimated to 6 for amount and difficulty scores and 4 for total score. Conclusions The D-PPAC and C-PPAC instruments are reliable and valid across diverse COPD populations and responsive to pharmacological and non-pharmacological interventions and changes in clinically relevant variables.
AB - Background The Daily-PROactive and Clinical visit-PROactive Physical Activity (D-PPAC and C-PPAC) instruments in chronic obstructive pulmonary disease (COPD) combines questionnaire with activity monitor data to measure patients' experience of physical activity. Their amount, difficulty and total scores range from 0 (worst) to 100 (best) but require further psychometric evaluation. Objective To test reliability, validity and responsiveness, and to define minimal important difference (MID), of the D-PPAC and C-PPAC instruments, in a large population of patients with stable COPD from diverse severities, settings and countries. Methods We used data from seven randomised controlled trials to evaluate D-PPAC and C-PPAC internal consistency and construct validity by sex, age groups, COPD severity, country and language as well as responsiveness to interventions, ability to detect change and MID. Results We included 1324 patients (mean (SD) age 66 (8) years, forced expiratory volume in 1 s 55 (17)% predicted). Scores covered almost the full range from 0 to 100, showed strong internal consistency after stratification and correlated as a priori hypothesised with dyspnoea, health-related quality of life and exercise capacity. Difficulty scores improved after pharmacological treatment and pulmonary rehabilitation, while amount scores improved after behavioural physical activity interventions. All scores were responsive to changes in self-reported physical activity experience (both worsening and improvement) and to the occurrence of COPD exacerbations during follow-up. The MID was estimated to 6 for amount and difficulty scores and 4 for total score. Conclusions The D-PPAC and C-PPAC instruments are reliable and valid across diverse COPD populations and responsive to pharmacological and non-pharmacological interventions and changes in clinically relevant variables.
KW - COPD epidemiology
KW - exercise
UR - http://www.scopus.com/inward/record.url?scp=85099844699&partnerID=8YFLogxK
U2 - 10.1136/thoraxjnl-2020-214554
DO - 10.1136/thoraxjnl-2020-214554
M3 - Article
C2 - 33479044
AN - SCOPUS:85099844699
SN - 0040-6376
VL - 76
SP - 228
EP - 238
JO - Thorax
JF - Thorax
IS - 3
ER -